← Back to patent-cliff list
恩曲他滨
Tier C — Watch / tradeEmtricitabine
Gilead Inc
Originator
2003
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：HIV-1 RT
Brand：Emtriva
Indications (approved)：HIV感染
Regional status
US
批准上市
2003-07-02
EU
批准上市
2003-10-24
China
批准上市
2005-11-18
Japan
批准上市
2005-03-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Emtricitabine?
Approved indications include: HIV感染.
When does the Emtricitabine patent expire?
No public expiry year is available for Emtricitabine yet; this page updates once verified.
How do I get a quote for Emtricitabine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25